Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259695 | 0.86 | MEN1 (0.43) | KMT2AMEN1 | |
| SCHEMBL4253013 | 0.85 | MAPT (0.42) | HTR2CHRH4KMT2AMEN1MAPT | |
| SCHEMBL13700290 | 0.84 | KDM4E (0.41) | HTR1BMAPTTP53TSHRAHR | |
| SCHEMBL13700060 | 0.84 | MEN1 (0.41) | KMT2AMEN1MAPTTP53TSHR | |
| SCHEMBL4253483 | 0.82 | TP53 (0.42) | KMT2AMEN1MAPTTP53TSHR | |
| SCHEMBL13700317 | 0.82 | KDM4E (0.43) | PTGDR2CSF1R | |
| SCHEMBL4259581 | 0.81 | MAPT (0.53) | KMT2AMEN1MAPTTP53TSHR | |
| SCHEMBL13700314 | 0.79 | KDM4E (0.40) | MAPTTP53TSHRAHRMAPK10 | |
| SCHEMBL13700315 | 0.79 | KDM4E (0.40) | KMT2AMEN1TSHR | |
| SCHEMBL4255128 | 0.78 | NPC1 (0.43) | KMT2AMEN1MAPTTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1710233-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | ADORA2A, ADORA2B, HTR1F | HTR2C 8/4885HTR1B 13/4885HRH4 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.